Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study
Florentia Dimitriou, Kenjiro Namikawa, Irene L. M. Reijers, Elizabeth I. Buchbinder, J. Soon, Anne Zaremba, Paweł Teterycz, Meghan J. Mooradian, Emma Armstrong, Yasuhiro Nakamura, Maria Grazia Vitale, Lena Tran, Xue Bai, Clara Allayous, S. Provent-Roy, Alice Indini, Prachi Bhave, Mohamad Farid, Katharina C. Kähler, Inderjit Mehmi, Victoria Atkinson, Oliver Klein, Connor J. Stonesifer, Farzana Y. Zaman, Andrew Haydon, Richard D. Carvajal, Omid Hamid, Reinhard Dummer, Axel Hauschild, Matteo S. Carlino, Mario Mandalà, Caroline Robert, Célèste Lebbé, Jun Guo, Douglas B. Johnson, Paolo A. Ascierto, Alexander N. Shoushtari, Ryan J. Sullivan, Bożena Cybulska-Stopa, Piotr Rutkowski, Lisa Zimmer, Shahneen Sandhu, Christian U. Blank, Serigne Lo, Alexander M. Menzies, Georgina V. Long (2022). Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. , 33(9), DOI: https://doi.org/10.1016/j.annonc.2022.06.004.
